Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
01:29pm, Thursday, 10'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Merck Announces Publication Of Positive Late-Stage Data For Keytruda-Chemo Combo In Breast Cancer
Merc
Viking Therapeutics (VKTX) Q4 2021 Earnings Call Transcript
07:31am, Thursday, 10'th Feb 2022 The Motley Fool
VKTX earnings call for the period ending December 31, 2021.
Viking Therapeutics (VKTX) Q4 2021 Earnings Call Transcript
07:31am, Thursday, 10'th Feb 2022 The Motley Fool
VKTX earnings call for the period ending December 31, 2021.
Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q4 2021 Results - Earnings Call
02:29am, Thursday, 10'th Feb 2022 Seeking AlphaViking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q4 2021 Results - Earnings Call
09:29pm, Wednesday, 09'th Feb 2022
Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q4 2021 Results - Earnings Call
Viking Therapeutics GAAP EPS of -$0.16 beats by $0.03
09:08pm, Wednesday, 09'th Feb 2022 Seeking Alpha
Viking Therapeutics press release (VKTX): Q4 GAAP EPS of -$0.16 beats by $0.03.
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
01:31pm, Wednesday, 09'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Humanigen Announces Agreement With French CDMO For Fill And Finish Services For Lenzilumab
Humanigen,
Viking Therapeutics Q4 2021 Earnings Preview
10:35pm, Tuesday, 08'th Feb 2022 Seeking Alpha
Viking Therapeutics (NASDAQ:VKTX) is scheduled to announce Q4 earnings results on Tuesday, February 8th, after market close.The consensus EPS Estimate is -$0.19 (-26.7% Y/Y) and…
Viking (VKTX) Study on X-ALD Put on Clinical Hold by the FDA
02:15pm, Wednesday, 26'th Jan 2022 Zacks Investment Research
Viking (VKTX) phase Ib study on VK0214 in patients with X-ALD put on hold by the FDA.
Viking (VKTX) Study on X-ALD Put on Clinical Hold by the FDA
10:45am, Wednesday, 26'th Jan 2022
Viking (VKTX) phase Ib study on VK0214 in patients with X-ALD put on hold by the FDA.
Why Viking Therapeutics Stock Got Mashed on Monday
11:42pm, Monday, 24'th Jan 2022 The Motley Fool
The clinical trial has been halted by the FDA for now, pending the submittal of a preclinical study.
Why Viking Therapeutics Stock Got Mashed on Monday
06:42pm, Monday, 24'th Jan 2022
The clinical trial has been halted by the FDA for now, pending the submittal of a preclinical study.
FDA puts clinical hold on Viking Therapeutics'' Phase 1b trial of VK0214 in X-ALD
12:30pm, Monday, 24'th Jan 2022 Seeking Alpha
Viking Therapeutics (VKTX) announces that its Phase 1b clinical trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD) has been placed on clinical hold by the FDA.The
Viking Therapeutics Stock (VKTX): Why The Price Substantially Went Down Today
11:53am, Monday, 24'th Jan 2022
The stock price of Viking Therapeutics Inc (NASDAQ: VKTX) fell by over 14% during intraday trading today. This is why it happened.
Viking Therapeutics' Early Stage Trial On FDA Hold In Rare Metabolic Disorder
07:33am, Monday, 24'th Jan 2022
The FDA has placed a clinical hold on Viking Therapeutics Inc's (NASDAQ: VKTX) Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). The FDA has requested an additiona
